Director Peter Thompson to not stand for re-election at Janux 2023 annual meeting

Janux Therapeutics, Inc.

Peter Thompson, M.D., informed Janux he will not stand for re-election to the Board at the 2023 annual meeting due to competing commitments.
Dr. Thompson's decision is not the result of any disagreement with the Company on operations, policies, or practices.
No replacement director has been announced as of the filing date.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Thompson

director

JANX · Janux Therapeutics, Inc.

Filed: March 31, 2023, 7:59 PM ET

On March 27, 2023, Peter Thompson, M.D., a director of Janux Therapeutics, Inc. (the “Company”), informed the Company that he does not intend to stand for re-election as a member of the Board of Directors at the Company’s 2023 annual meeting of stockholders as a result of competing commitments.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Thompson departed as director at Janux Therapeutics, Inc..

Action: does not intend to stand for re-election
Role: director

Exact text from the filing

On March 27, 2023, Peter Thompson, M.D., a director of Janux Therapeutics, Inc. (the “Company”), informed the Company that he does not intend to stand for re-election as a member of the Board of Directors at the Company’s 2023 annual meeting of stockholders as a result of competing commitments.

View on SEC.gov

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-011433

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.